ALGS (Aligos Therapeutics) Net Loan


ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $6.63
GF Value $2.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

ALGS
37GF Score
Aligos Therapeutics Inc ALGS
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • Net Loan:
  • GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price
$2.78
GF Value